What is Intuitive Surgical's primary revenue driver, and how is it performing?

Intuitive Surgical's primary revenue driver is the sale of its da Vinci Surgical System. The company reported strong growth in this area, with sales of the system increasing in unit volume and contributing to a 38% rise in total sales for the third quarter of 2001 and a 124% increase for the first nine months of 2001.

Is Intuitive Surgical profitable, and what is its path to profitability?

Intuitive Surgical is currently operating at a net loss, reporting a loss of $4.8 million for the third quarter and $12.4 million year-to-date. While gross profit margins are improving significantly due to increased sales and manufacturing efficiencies, operating expenses for R&D and SG&A are also increasing to support growth. The company expects to continue investing in these areas and acknowledges that achieving profitability is uncertain and may take time.

What are the key financial risks facing Intuitive Surgical based on this filing?

The key financial risks identified include the ongoing net losses, the long and variable sales cycles for its high-value da Vinci system, dependence on a small number of customers for a substantial portion of revenue, and significant ongoing patent litigation with competitors like Computer Motion. The outcome of these legal battles could result in substantial damages, injunctions preventing product sales, or costly licensing agreements.

How is the company managing its liquidity and capital resources?

Intuitive Surgical maintains a strong liquidity position with $64.3 million in cash and short-term investments as of September 30, 2001. The company expects these resources, along with anticipated revenue, to be sufficient to fund operations through at least 2002. They may need to raise additional capital through debt or equity in the future, but are mindful of potential dilution from equity sales.

ISRG 10-Q Quarterly Report Q3 FY2001 — Revenue, Net Income, EPS

Summary

Intuitive Surgical Inc. (ISRG) reported its third-quarter and nine-month results for the period ending September 30, 2001. The company continues to demonstrate strong revenue growth, with sales increasing by 38% for the quarter and 124% year-to-date, driven by a significant rise in the number of da Vinci Surgical Systems sold. This top-line growth is translating into improved profitability at the gross margin level, which increased to 47% for both the quarter and year-to-date periods, up from 40% and 33% respectively in the prior year, reflecting improved manufacturing efficiencies. Despite the revenue and gross profit improvements, the company continues to operate at a net loss, albeit a slightly reduced one for the nine-month period compared to the prior year. Operating expenses, particularly in research and development and selling, general, and administrative functions, have increased to support product development and sales expansion. The company's liquidity remains strong, with a substantial balance of cash and short-term investments, and management expects these resources to fund operations through at least 2002. However, the company is actively engaged in significant patent litigation with competitors, which poses a considerable risk and could impact future financial performance and product availability.

Key Highlights

1Revenue increased significantly, up 38% to $10.9 million for the three months ended September 30, 2001, and up 124% to $35.7 million for the nine months ended September 30, 2001.
2Gross profit margin improved to 47% for the nine months ended September 30, 2001, from 33% in the same period of 2000, driven by sales growth and manufacturing efficiencies.
3The company sold 10 da Vinci Surgical Systems in Q3 2001, up from 8 in Q3 2000, and 34 year-to-date in 2001, compared to 17 in the same period of 2000.
4Operating expenses, specifically R&D and SG&A, increased to support growth, with R&D up 10% and SG&A up 38% for the quarter.
5Despite revenue growth, the company continued to incur net losses, with a net loss of $4.8 million for the quarter and $12.4 million year-to-date.
6Cash and short-term investments totaled $64.3 million as of September 30, 2001, providing ample liquidity.
7The company is involved in significant ongoing patent litigation with Computer Motion, Inc. and Brookhill-Wilk 1, LLC, posing potential risks to its competitive position and product sales.

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2001

Summary

Key Highlights

Frequently Asked Questions